SOMATROPIN MARKET ANALYSIS

Global somatropin market is estimated to be valued at US$ 3.85 Billion in 2023 and is expected to exhibit a CAGR of 7.3% during the forecast period (2023-2030).

Analysts’ Views on Global Somatropin Market:

The growth of the global somatropin market is anticipated to be driven by rising product approval by regulatory bodies, rising product launches by major market players, and rising long-term effects of growth hormone therapy on children with growth hormone deficiency. For instance, in October 2020, Erasmus Medical Center, an innovative university medical center in collaboration with Pfizer, Inc., a multinational pharmaceutical and biotechnology corporation, foundation for Prader-Willi Research, a research Centre oriented for Prader-Willi and Prader-Willi Fonds, initiated a Phase III clinical trial to assess the effect of growth hormone treatment (Genotropin) on physical and psychosocial health in adults of 30 years or older with Prader-Willi syndrome.

Figure 1. Global Somatropin Market Share (%), By Dosage Form, 2023

To learn more about this report, request sample copy

Global Somatropin Market– Drivers

Product approval from regulatory authorities

Product approval from regulatory authorities such as U.S. Food and Drug Administration is expected to drive the market over the forecast period. On June 28 2023, Pfizer Inc., a multinational pharmaceutical and biotechnology corporation and OPKO Health Inc., a medical test and medication company, focused on diagnostics and pharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone. NGENLA is expected to become available for U.S. prescribing in August 2023.

Increasing long term effect of growth hormone therapy on children with growth hormone deficiency

Increasing long term effect of growth hormone therapy on children with growth hormone deficiency is expected to drive the global somatropin market growth over the forecast period. For instance, in July 2022, according to the data published in the Journal Acta Biomedica, in 2020, a study was conducted among 252 short children with growth hormone deficiency, 63 with idiopathic short stature, 26 with small for gestational age, and 9 with Turner syndrome who were treated in King Abdullah International Medical Research Center, Jeddah, Saudi Arabia with growth hormone.

Figure 2. Global Somatropin Market Share (%), By Region, 2023

To learn more about this report, request sample copy

Global Somatropin Market- Regional Analysis

Among region, North America is estimated to hold a dominant position in the global somatropin market over the forecast period owing to the increase in the product launch by the key market players and increase in the prevalence of turner syndrome. For instance, in August 2022, according to an article published in the Journal of StatPearls, Turner syndrome is seen in about 1 in 2000 to 1 in 2500 live female births take place in U.S. in 2020 and this count is estimated to increase to about 2 in 2000 female births by 2025.

Global Somatropin Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others faced problems regarding transportation of drugs from one place to another.

COVID-19 had a negative impact on the global somatropin market owing to the disturbance in the supply chain of the drug through distribution channel. The COVID-19 pandemic has affected clinical trials drastically. For instance, on April 23, 2020, according to a survey conducted by Medidata Solutions, Inc., a company which markets and develops software as a service for clinical trials, conducted a survey which showed observations such as 63% of survey respondents reported that they had stopped recruiting new patients for ongoing clinical trials and 43% of the respondents had postponed their studies. Moreover, since the COVID-19 virus outbreak, the supply chain of growth hormone deficiency drugs was hampered and the somatropin market was affected in a negative way, however the market recovery was seen over the late phase of COVID-19.

Global Somatropin Market- Segmentation

The global somatropin market report is segmented into dosage form, application, distribution channel, and region.

Among Dosage Form, the global somatropin market is segmented into solvent and powder. Out of which, the powder segment is expected to dominate the market during the forecast period and this is attributed due to the increase bioavailability of growth hormone to treat growth failure in children and adults who lack natural growth hormone and improve patient compliance as compared to the solvent form.

Among Application, the global somatropin market is segmented into growth hormone deficiency (GHD), turner syndrome, chronic renal insufficiency, prader willi syndrome, small for gestational age, SHOX deficiency, and others. The plant-based segment is expected to dominate the market over the forecast period and this is attributed owing to the increase in incidence of turner syndrome across the globe.

Based on Distribution channel, the global somatropin market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to dominate the market over the forecast period and this is attributed to the preference and ease of availability of artificial or recombinant human growth hormone in hospital pharmacies.

Among Region, the global somatropin market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Out of which, the North America is expected to dominate the market over the forecast period owing to the increase in launch of product by market key players and increase in the prevalence of turner syndrome.

Among all segmentation, the application segment has the highest potential due to the increasing product launch as well as increase in the prevalence of turner syndrome over the forecast period. For instance, on May 31 2023, according to an article published by the Everyday Health, Turner syndrome is a rare condition, estimated to occur in about 1 of every 2,000 to 2,500 live female births in U.S in 2021.

Global Somatropin Market- Cross Sectional Analysis

Among application, the turner syndrome segment held a dominant position in North America region over the forecast period due to the increase in prevalence of turner syndrome which is expected to drive segment growth over the forecast period. For instance, on March 15 2023, according to an article published in the Journal of American Journal of Medical Genetics, in U.S, Turner syndrome occurred in 3.2 per 10,000 live births of females overall and 1.9 per 10,000 live births and stillbirths (20 weeks gestation) situations in 2021. Prevalence was lowest among cases born to non-Hispanic Black women compared to non-Hispanic White women.

Global Somatropin Market- Key Developments

On April 28 2023, Novo Nordisk A/S, a global healthcare company, announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Sogroya (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg for the treatment of children aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone. With this new indication, Sogroya becomes the first and only once-weekly growth hormone (GH) treatment for both children and adults. The FDA approval of the new indication for children with GHD is based on data from the phase 3 REAL4 study.

In November 2020, Aeterna Zentaris, a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, announced that it has entered into an amendment of its existing License Agreement with Novo Nordisk A/S, a global healthcare company related to the development and commercialization of macimorelin, which is used for the diagnosis of adult growth hormone deficiency (AGHD).

In January 2020, Ferring B.V., a biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has approved ZOMACTON (somatropin) for Injection 5 mg and 10 mg recombinant human growth hormone (GH) indicated for replacement of GH in adults with GH deficiency.

In April 2021, Merck KGaA, a multinational science and technology company, has signed up with PRA Health Sciences to wed its human growth hormone (HGH) treatment system with the CRO’s remote patient monitoring platform. Under the terms of this new agreement, the financial details of which were not made public, PRA's platform will support Merck's HGH treatment system, including grow link, an app for patients who are prescribed the pharmaceutical company's HGH treatment, known as Saizen (somatropin), and easy pod Connect, a platform for endocrinology professionals to monitor patients' adherence, review injection histories, and share information about patients' progression.

In February 2022, Pfizer Inc., a multinational pharmaceutical and biotechnology corporation, and OPKO Health, Inc., a medical test and medication company focused on diagnostics and pharmaceuticals, announced that the European Commission has granted marketing authorization for the next-generation long-acting recombinant human growth hormone NGENLA (somatrogon), a once-weekly injection to treat children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone. NGENLA provides pediatric patients, their caregivers and healthcare providers with a new treatment option for growth hormone deficiency (GHD) that reduces the frequency of required injections from once daily to once weekly.

Global Somatropin Market- Key Trends

Increasing awareness about the growth hormone deficiency

Increasing awareness about the growth hormone deficiency is expected to drive the market over the forecast period. For instance, in February 2020, The Section of Endocrinology and the Department of Pediatrics announced Growth Online Awareness Campaign on the Growth Awareness Day, which will be held at King Faisal Specialist Hospital and Research Centre- Saudi Arabia. This was an online campaign titled Growth Online Awareness Campaign, which will drive the awareness of growth hormones deficiency and treatment methods for it.

Global Somatropin Market: Restraints

Increasing presence of alternative drugs for growth hormone deficiency

Increasing presence of alternative drugs for growth hormone deficiency is expected to hinder the market growth over the forecast period. So, research & development in developing novel and innovative growth hormone delivery can be initiated by the key market players to avoid the presence of alternative therapies. For instance, in June 2022 according to an article published by Healthline Media LLC, a website and provider of health information, Sermorelin therapy is less expensive than human growth hormone treatment, sometimes by as much as 10%. Injection or a multi-dose auto pen are two alternatives for administration of drug.

Global Somatropin Market- Key Players

Major players operating in the global somatropin market include Novo Nordisk A/S, Pfizer, Inc., Eli Lilly and Company, Changchun GeneScience Pharmaceutical Co., Ltd., Sandoz International GmbH, Ipsen Pharma, LG Chem, Merck KGaA, Genentech, Inc., Ferring B.V., AnkeBio Co., Ltd, Reliance Life Sciences, JCR Pharmaceuticals Co., Ltd, Zhongshan Sinobioway Hygene Biomedicine Co., Ltd, and USV Private Limited.

*Definition: Somatropin is a recombinant human growth hormone indicated for the treatment of growth hormone deficiency in children and adults, as well as Turner syndrome, Prader-Willi syndrome, Chronic Renal Insufficiency (chronic kidney disorder), and others. Somatropin stimulates linear growth (height), tissue growth, and lipid, protein, carbohydrate, and mineral metabolism. Injections of somatropin are used to treat growth hormone insufficiency in both adults and children. Growth hormone is a natural hormone produced by the body. Children with specific diseases,  such as Growth hormone deficiency (GHD),that hinder normal growth and development can potentially benefit from somatropin injections to accelerate their growth.